CD4 and type 2 diabetes mellitus: In contrast, among the CoronaVac vaccinees, only 60-80% of HCs had detectable circulating S-reactive CD4+T cells following S1 peptide stimulation, and this proportion further reduced to 24-36% in participants with type 2 diabetes.